VIMPAT INJECTION

Compare VIMPAT INJECTION  to:
Compare
Compare

Generic Name for VIMPAT INJECTION

Lacosamide 10mg/mL; soln for IV infusion.

Legal Classification:

CV

Pharmacological Class for VIMPAT INJECTION

Sodium channel inactivator.

Manufacturer of VIMPAT INJECTION

UCB Inc.

Indications for VIMPAT INJECTION

Adjunct in partial-onset seizures, when oral administration is not feasible.

Adult dose for VIMPAT INJECTION

Inj: may give without diluting, or mix in appropriate diluent and give by IV infusion over 30–60min. For oral and inj: ≥17yrs: initially 50mg twice daily; may increase at weekly intervals by 100mg/day in 2 divided doses . Maintenance dose: 200–400mg/day. Renal impairment (CrCl≤30mL/min), ESRD, mild-moderate hepatic impairment: max 300mg/day. Consider supplemental dose (50%) after hemodialysis. Avoid abrupt cessation (withdraw over 1 week).

Children's dosing for VIMPAT INJECTION

<17yrs: not recommended.

Also:

Precautions for VIMPAT INJECTION

Severe hepatic impairment: not recommended. Cardiac conduction disturbances (eg, 2nd degree AV block). Severe cardiac disease (eg, myocardial ischemia, heart failure). Monitor for suicidal ideation, depression. Diabetic neuropathy. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for VIMPAT INJECTION

Caution with other drugs that cause PR prolongation.

Adverse Reactions for VIMPAT INJECTION

Dizziness, ataxia, diplopia, headache, GI upset, syncope; rare: multiorgan hypersensitivity reaction.

How is VIMPAT INJECTION supplied?

Tabs—60, 180
Single-use vials (20mL)—10

Related Disease:

Epilepsy
Seizure disorders

Related Resources

Lamictal XR approved as add-on therapy for primary generalized tonic-clonic seizures

February 01, 2010

The FDA has approved Lamictal XR (lamotrigine extended-release tablets, from GlaxoSmithKline) as a once daily, add-on therapy for epilepsy in patients ≥13 years of age with primary generalized tonic-clonic seizures.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA accepts NDA for retigabine, a treatment for partial-onset seizures

January 04, 2010

Valeant has announced that the FDA has accepted for review the New Drug Application (NDA) for retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.

Sabril available for infantile spasms and adult epileptic seizures

September 21, 2009

Lundbeck has made available Sabril (vigabatrin) powder for oral solution and tablets for the treatment of infantile spasms and refractory complex partial seizures.